What to Expect From Allergan Earnings
Allergan is scheduled to report its second-quarter financial results Thursday before the markets open.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 254Will Biogen Win From Novartis MS Drug Safety Label Change?
ThinkstockThere are times when a negative piece of news in the BioPharma sector can actually help rival companies. Biogen Inc. (NASDAQ: BIIB) is a stock that has been battered of late, and it is…
Starboard Value Sets Its Eyes on MedAssets
In an open letter to the chairman and CEO of MedAssets, Starboard Value outlines a plan to create more value, reduce operating expenses and improve capital allocation.
UBS Makes August Changes to Equity Focus List Portfolio
In a new report, UBS made changes in the firm's Equity Focus list and updated other positions.
3 Potential Huge Takeover Targets in Biotech
In a new research report, Cowen's well-respected analyst Ken Cacciatore makes a very good case that some huge, high-profile biotech companies could be targeted for buyouts.
Independent Research Firm Sees Higher Upside in Amgen
According to Argus, second-quarter earnings, along with a strong pipeline and general outlook, have positioned Amgen to take the market by storm.
Positive Developments Around Ebola
Ebola fears have subsided and the development of a vaccine or related drugs has been put on the back burner for most, but one biotech made waves in the market Monday morning.
3 Biotech Stocks to Buy With Huge Catalysts Coming Soon
SunTrust Robinson Humphrey handicaps some of the upcoming events for stocks in the firm's coverage universe that have potential market-moving clinical and FDA catalysts during the remainder of 2015.
INC Research Files for Secondary Offering
INC Research Holdings has filed with the Securities and Exchange Commission (SEC) for a secondary offering.
Zynerba Updates IPO Terms
Zynerba Pharmaceuticals has amended its filing with the Securities and Exchange Commission (SEC) for its initial public offering
Teva Proves Its Decade-Hold Status With Massive Funding
ThinkstockTeva Pharmaceutical Industries Ltd. (NYSE: TEVA) may have just proved how financially fit and capable the company is. On Friday afternoon the global generic drug giant reported that it has secured financing of $33.75…
Global Blood Therapeutics Updates Terms in IPO
ThinkstockGlobal Blood Therapeutics Inc. filed an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO). The expected price range is anticipated to be $16 to $18…
Amgen Earnings Point to New 52-Week High
ThinkstockAmgen Corp. (NASDAQ: AMGN) reported fiscal second quarter 2015 earnings Thursday afternoon after equity markets had closed. The biotech firm posted adjusted earnings per share (EPS) of $2.57 on revenues of $5.37 billion. In…
Why Merrill Lynch Upgraded Aetna
ThinkstockMerrill Lynch upgraded Aetna Inc. (NYSE: AET) to Buy from Neutral but maintains its price objective at $132, implying an 18% upside. Since the announcement that Aetna will acquire Humana on July 3, shares…
What to Expect from Amgen Earnings
ThinkstockAmgen Inc. (NASDAQ: AMGN) is scheduled to report its earnings after the markets close on Thursday. There are consensus estimates from Thomson Reuters that call for $2.43 in earnings per share (EPS) on $5.32…